Schizophrenia News

Areas with high levels of social fragmentation had higher rates of psychosis, according to results of a systematic review published in Journal of Clinical Psychiatry.

FDA recently approved Lybalvi for the treatment of schizophrenia and for use in manic and mixed (depressive and manic) episodes of bipolar I disorder as an acute treatment, a maintenance treatment, and for use with valproate or lithium.

Loneliness may signal underlying psychotic experiences among adolescents, according to results of a population-based birth cohort study published in Schizophrenia Research.

The number of psychiatrists who provided psychotherapy significantly declined between 1996 and 2016, according to study results published in American Journal of Psychiatry.

A 26-week, randomized, double-blind, placebo-controlled phase 2 study showed pimavanserin reduced negative schizophrenia symptoms in stable patients.

Neurocrine Biosciences and Sosei Group Corporation have announced a partnership to create a new brand of protein inhibitor that the former plans to study to improve treatments for a wide range of neuropsychiatric disorders.

Patients with major psychiatric disorders appeared to have higher rates of medical comorbidities linked to worse COVID-19 outcomes, according to results of a cross-sectional study published in JAMA Network Open.

In conjunction with Veterans Day, Healio Psychiatry has compiled a list of recent research related to veteran mental health.

Paliperidone palmitate appeared to benefit Black patients with recent-onset schizophrenia or schizophreniform disorder, according to study results presented at NEI Congress.

Prescription opioid dispensing decreased for patients with schizophrenia, as well as those with bipolar disorder, between 2015 and 2019, according to study results presented at NEI Congress.